DarioHealth Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DarioHealth in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DarioHealth stock.
View analyst ratings for DarioHealth or view top-rated stocks.

Wall Street analysts have given DarioHealth a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but DarioHealth wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

DarioHealth saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 280,000 shares, an increase of 58.8% from the February 28th total of 176,300 shares. Based on an average trading volume of 274,400 shares, the days-to-cover ratio is currently 1.0 days. Approximately 2.4% of the company's shares are short sold.
View DarioHealth's Short Interest.

DarioHealth is scheduled to release its next quarterly earnings announcement on Tuesday, May 11th 2021.
View our earnings forecast for DarioHealth.

DarioHealth Corp. (NASDAQ:DRIO) released its quarterly earnings data on Monday, March, 8th. The company reported ($1.06) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.62) by $0.44. The company earned $2.08 million during the quarter, compared to analyst estimates of $2.12 million. DarioHealth had a negative net margin of 337.55% and a negative trailing twelve-month return on equity of 120.46%.
View DarioHealth's earnings history.

DarioHealth's stock was trading at $6.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DRIO stock has increased by 167.8% and is now trading at $18.45.
View which stocks have been most impacted by COVID-19.

DarioHealth updated its FY 2020 Pre-Market earnings guidance on Wednesday, January, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $7.6-7.6 million, compared to the consensus revenue estimate of $7.63 million.

7 brokerages have issued twelve-month price objectives for DarioHealth's shares. Their forecasts range from $10.00 to $35.00. On average, they anticipate DarioHealth's share price to reach $25.75 in the next twelve months. This suggests a possible upside of 39.6% from the stock's current price.
View analysts' price targets for DarioHealth or view top-rated stocks among Wall Street analysts.

Some companies that are related to DarioHealth include LeMaitre Vascular (LMAT), OrthoPediatrics (KIDS), Cerus (CERS), AngioDynamics (ANGO), CryoLife (CRY), Orthofix Medical (OFIX), Surmodics (SRDX), OraSure Technologies (OSUR), Invo Bioscience (IVOB), Intersect ENT (XENT), Antares Pharma (ATRS), Anika Therapeutics (ANIK), SeaSpine (SPNE), Vapotherm (VAPO) and Pulse Biosciences (PLSE).
View all of DRIO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other DarioHealth investors own include Aeterna Zentaris (AEZS), Vascular Biogenics (VBLT), Nano Dimension (NNDM), Pluristem Therapeutics (PSTI), CorMedix (CRMD), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), ADMA Biologics (ADMA) and Avadel Pharmaceuticals (AVDL).

DarioHealth trades on the NASDAQ under the ticker symbol "DRIO."

DarioHealth's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Calamos Advisors LLC (0.10%). Company insiders that own DarioHealth stock include Adam K Stern, Erez Raphael and Yoav Shaked.
View institutional ownership trends for DarioHealth.

DRIO stock was purchased by a variety of institutional investors in the last quarter, including Calamos Advisors LLC. Company insiders that have bought DarioHealth stock in the last two years include Adam K Stern, Erez Raphael, and Yoav Shaked.
View insider buying and selling activity for DarioHealth or or view top insider-buying stocks.

Shares of DRIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DRIO stock can currently be purchased for approximately $18.45.

DarioHealth has a market capitalization of $284.11 million and generates $7.56 million in revenue each year. The company earns $-17,740,000.00 in net income (profit) each year or ($8.00) on an earnings per share basis.

DarioHealth employs 127 workers across the globe.

The official website for DarioHealth is www.mydario.com.

DarioHealth is headquartered at 8 HaToKhen Street, Caesarea Industrial Park L3, 3088900.

DarioHealth's mailing address is 8 HaToKhen Street, Caesarea Industrial Park L3, 3088900. The company can be reached via phone at 972-4770-4055 or via email at [email protected]